DANIPOP: Non Invasive Diagnosis of Pneumocystis Pneumonia
Study Details
Study Description
Brief Summary
Incidence and morbi-mortality of Pneumocystis pneumonia (PCP) are increasing. Early and fast diagnosis and treatment improve PCP prognosis. Biological diagnosis is based on the detection of Pneumocystis jirovecii, mainly by PCR, in broncho-alveolar lavage (BAL) obtained from bronchial fibroscopy. However this invasive exam is not always possible in emergency in suspected patient and others non invasive (sputa) and/or non-targeted (bronchial aspiration) are sent to the laboratory (25% of cases, data from the Grenoble University Hospital). Diagnosis performances of these non invasive/non-targeted samples are not clearly established.
In this study, the investigators aimed to establish the diagnosis value of non-invasive and/or non-targeted respiratory samples (oral fluids, sputa and bronchial aspiration) for the PCP diagnosis, compared to the gold-standard (Pneumocystis PCR on BAL, beta-D-glucans testing on serum and radio-clinical records).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Case : confirmed PCP diagnosis Sampling of non-invasive and/or non-targeted respiratory tract specimens |
Diagnostic Test: Sampling of non-invasive and/or non-targeted respiratory tract specimens
Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
|
| Other: Control : non confirmed PCP diagnosis Sampling of non-invasive and/or non-targeted respiratory tract specimens |
Diagnostic Test: Sampling of non-invasive and/or non-targeted respiratory tract specimens
Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
|
Outcome Measures
Primary Outcome Measures
- Sensitivity [30 months]
Sensitivity of Pneumocystis PCR on non-invasive and/or non-targeted respiratory samples compared to the gold-standard
- Specificity [30 months]
Specificity of Pneumocystis PCR on non-invasive and/or non-targeted respiratory samples compared to the gold-standard
- Area Under the Curve (AUC) [30 months]
AUCs of Pneumocystis PCR on non-invasive and/or non-targeted respiratory samples compared to the gold-standard
- Estimation of the positive predictive value [30 months]
Estimation of the predictive values of Pneumocystis PCR on non-invasive and/or non-targeted respiratory samples compared to the gold-standard
- Estimation of the negative predictive value [30 months]
Estimation of the negative predictive values of Pneumocystis PCR on non-invasive and/or non-targeted respiratory samples compared to the gold-standard
Secondary Outcome Measures
- Time-saving (in hours) of PCP diagnosis on non-invasive and/or non-targeted respiratory samples compared to the PCP diagnosis on BAL, taking into account the time needed for bronchial fibroscopy [30 months]
- Optimal cut-off values for interpretation of Pneumocystis fungal load on non-invasive and/or non-targeted respiratory samples [30 months]
- Duration of anti-PCP treatment (days) [30 months]
Impact of PCP diagnosis on non-invasive and/or non-targeted respiratory samples on the patient management
- Estimation of the number of days of presumptive anti-PCP treatment that would have been avoided based on a PCP diagnosis on non-invasive and/or non-targeted respiratory samples [30 months]
Impact of PCP diagnosis on non-invasive and/or non-targeted respiratory samples on the patient management
- Estimation of the number of patients who would have received an earlier appropriate anti-PCP treatment based on a PCP diagnosis on non-invasive and/or non-targeted respiratory samples [30 months]
Impact of PCP diagnosis on non-invasive and/or non-targeted respiratory samples on the patient management
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Immunocompromised patient with (i) clinical and/or radiological suspicion of PCP, and (ii) bronchial fibroscopy with contributive BAL
-
No immediate life-threatening conditions (estimated life expectancy >12h)
-
No PCP treatment or PCP treatment < 48h
-
Patient hospitalized in the Grenoble Alpes University Hospital with medical insurance
-
Informed and written consent of the patient or its related
Exclusion Criteria:
-
Pregnancy, breastfeeding
-
Exclusion period of another clinical trial
-
Deprivation of liberty
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Grenoble Alpes University Hospital | Grenoble | France | 38043 |
Sponsors and Collaborators
- University Hospital, Grenoble
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 38RC17.281
- 2017-A02651-52